The purpose of this in vitro study was to assess the potential benefits of eye drops based on hybrid cooperative complexes (HCCs) obtained from high and low molecular weight hyaluronic acid (HA).
Methods:
Rheological measurements were performed to adjust the HCC concentration toward optimal resistance to drainage from the ocular surface. The viscosity and mucoadhesion profiles of the optimized preparation were derived. Primary porcine corneal epithelial cells were used for biological studies. Cells were exposed to dehydration after being pretreated with the HCC solution, and protection from desiccation was evaluated using cell viability assays. Time-lapse experiments were carried out to evaluate the ability of the HCC preparation to promote corneal wound healing. The characterization studies were performed in comparison with a control HA solution representative of commercial HA-based products.
Results:
The HCC formulation is able to deliver twice the amount of biopolymer compared with conventional products while avoiding discomfort due to excessive viscosity. The viscosity and mucoadhesion profiles allowed the authors to predict the longer in vivo retention and, therefore, an improved HCC formulation bioavailability. The new preparation also proved superior in protecting porcine corneal epithelial cells from desiccation and in hastening corneal cell wound repair in vitro.
Conclusions:
The results suggest that the developed formulation may be a promising topical ophthalmic medical treatment.
Get full access to this article
View all access options for this article.
References
1.
RangarajanR., KraybillB., OgundeleA., and KetelsonH.A.Effects of a hyaluronic acid/hydroxypropyl guar artificial tear solution on protection, recovery, and lubricity in models of corneal epithelium. J. Ocul. Pharmacol. Ther. 31:491–497, 2015.
2.
Di ColoG., ZambitoY., ZainoC., and SansòM.Selected polysaccharides at comparison for their mucoadhesiveness and effect on precorneal residence of different drugs in the rabbit model. Drug Dev. Ind. Pharm. 35:941–949, 2009.
3.
LudwigA.The use of mucoadhesive polymers in ocular drug delivery. Adv. Drug Deliv. Rev. 57:1595–1639, 2005.
4.
SnibsonG.R., GreavesJ.L., SoperN.D.W., et al.Precorneal residence times of sodium hyaluronate solutions studied by quantitative gamma scintigraphy. Eye. 4:594–602, 1990.
5.
CamillieriG., BucoloC., RossiS., and DragoF.Hyaluronan-induced stimulation of corneal wound healing is a pure pharmacological effect. J. Ocul. Pharmacol. Ther. 20:548–553, 2004.
6.
GomesJ.A.P., AmankwahR., Powell-RichardsA., and DuaH.S.Sodium hyaluronate (hyaluronic acid) promotes migration of human corneal epithelial cells in vitro. Br. J. Ophthalmol. 88:821–825, 2004.
7.
ZhongJ., DengY., TianB., et al.Hyaluronate acid-dependent protection and enhanced corneal wound healing against oxidative damage in corneal epithelial cells. J. Ophthalmol. 2016:6538051, 2016.
8.
LinT., and GongL.Sodium hyaluronate eye drops treatment for superficial corneal abrasion caused by mechanical damage: a randomized clinical trial in the People's Republic of China. Drug Des. Dev. Ther. 9:687–694, 2015.
9.
InoueM., and KatakamiC.Invest. The effect of hyaluronic acid on corneal epithelial cell proliferation. Ophtalmol. Vis. Sci. 34:2313–2315, 1993.
SugiyamaT., MiyauchiS., MachidaA., et al.The effect of sodium hyaluronate on the migration of rabbit corneal epithelium, II: the effect of topical administration. J. Ocul. Pharmacol. 7:53–64, 1991.
12.
AragonaP., Di StefanoG., FerreriF., SpinellaR., and StiloA.Sodium hyaluronate eye drops of different osmolarity for the treatment of dry eye in Sjögren's syndrome patients. Br. J. Ophthalmol. 86:879–884, 2002.
13.
ZambitoY., and Di ColoG. (2011) Polysaccharides as excipients for ocular topical formulations. www.intechopen.com Accessed October5, 2018.
14.
ZhengX., GotoT., ShiraishiA., and OhashiY.In vitro efficacy of ocular surface lubricants against dehydration. Cornea. 32:1260–1264, 2013.
15.
LiaoY.H., JonesS.A., ForbesB., MartinG.P., and BrownM.B.Hyaluronan: pharmaceutical characterization and drug delivery. Drug Deliv. 12:327–342, 2005.
16.
TongL., PetznikA., YeeL.S., and TanJ.Choice of artificial tear formulation for patients with dry eye: where do we start?. Cornea. 31:S32–S36, 2012.
17.
GuillaumieF., FurrerP., Felt-BaeyensO., et al.Comparative studies of various hyaluronic acids produced by microbial fermentation for potential topical ophthalmic applications. J. Biomed. Mater. Res. 92A:1421–1430, 2010.
18.
JohnsonM.E., MurphyP.J., and BoultonM.Effectiveness of sodium hyaluronate eyedrops in the treatment of dry eye. Graef Arch. Clin. Exp. 244:109–112, 2006.
19.
LiuX.M., HarmonP.S., MaziarzP., RahM.J., and MercheaM.M.Comparative studies of hyaluronan in marketed ophthalmic products. Optom. Vis. Sci. 91:32–38, 2014.
20.
McDonaldC.C., KayeS.B., FigueiredoF.C., MacintoshG., and LockettC.A.randomised, crossover, multicentre study to compare the performance of 0.1% (w/v) sodium hyaluronate with 1.4% (w/v) polyvinyl alcohol in the alleviation of symptoms associated with dry eye syndrome. Eye. 16:601–607, 2002.
21.
SalzilloR., SchiraldiC., CorsutoL., et al.Optimization of hyaluronan-based eye drop formulations. Carbohydr. Polym. 153:275–283, 2016.
22.
Uccello-BarrettaG., NazziS., ZambitoY., et al.Synergistic interaction between TS-polysaccharide and hyaluronic acid: implications in the formulation of eye drops. Int. J. Pharm. 395:122–131, 2010.
23.
OechsnerM., and KeipertS.Polyacrylic acid/polyvinylpyrrolidonebiopolymeric systems. I. Rheological and mucoadhesive properties offormulations potentially useful for the treatment of dry-eye-syndrome. Eur. J. Pharm. Biopharm. 47:113–118, 1999.
24.
PiresN.R., CunhaP.L.R., MacielJ.S., et al.Sulfated chitosan as tear substitute with no antimicrobial activity. Carbohydr. Polym. 91:92–99, 2013.
25.
D'AgostinoA., StellavatoA., BusicoT., et al.In vitro analysis of the effects on wound healing of high- and low-molecular weight chains of hyaluronan and their hybrid H-HA/L-HA complexes. BMC Cell. Biol. 16:19–33, 2015.
26.
StellavatoA., CorsutoL., D'AgostinoA., et al.Hyaluronan hybrid cooperative complexes as a novel frontier for cellular bioprocesses re-activation. PLoS One. 11:1–20, 2016.
27.
De RosaM., D'AgostinoA., La GattaA., and SchiraldiC. WO Patent WO/2012/032,151.
28.
D'AgostinoA., StellavatoA., CorsutoL., et al.Is molecular size a discriminating factor in hyaluronan interaction with human cells?. Carbohydr. Polym. 157:21–30, 2017.
29.
FergusonE.L., RobertsJ.L., MoseleyR., GriffithsP.C., and ThomasD.W.Evaluation of the physical and biological properties of hyaluronan and hyaluronan fragments. Int. J. Pharm. 420:84–92, 2011.
30.
SternR., AsariA.A., and SugaharaK.N.Hyaluronan fragments: an information-rich system. Eur. J. Cell. Biol. 85:699–715, 2006.
31.
David-RaoudiM., TranchepainF., DeschrevelB., et al.Differential effects of hyaluronan and its fragments on fibroblasts: relation to wound healing. Wound Repair Regen. 16:274–287, 2008.
32.
La GattaA., De RosaM., MarzaioliI., BusicoT., and SchiraldiC.A complete hyaluronan hydrodynamic characterization using a triple detector-SEC system during in vitro enzymatic degradation. Anal. Biochem. 404:21–29, 2010.
33.
La GattaA., SchiraldiC., PapaA., and De RosaM.Comparative analysis of commercial dermal fillers based on crosslinked hyaluronan: physical characterization and in vitro enzymatic degradation. Polym. Degrad. Stabil. 96:630–636, 2011.
34.
La GattaA., SchiraldiC., PapaA., et al.Hyaluronan scaffolds via diglycidyl ether crosslinking: toward improvements in. composition and performance. Carbohydr. Polym. 96:536–544, 2013.
35.
La GattaA., PapaA., SchiraldiC., and De RosaM.Hyaluronan dermal fillers via crosslinking with 1,4-butandiol diglycidyl ether: exploitation of heterogeneous reaction conditions. J. Biomed. Mater. Res. 104:9–18, 2016.
36.
HassanE.E., and GalloJ.M.A simple rheological method for the in vitroassessment of mucin-polymer bioadhesive bond strength. Pharm. Res. 7:491–495, 1990.
37.
BaranowskiP., KarolewiczB., GajdaM., and PlutaJ.Ophthalmic drug dosage forms: characterisation and research methods. Sci. World J. 2014:14 pages, Article ID 861904
38.
MatsudaT., HiraokaS., UrashimaH., OguraA., and IshidaT.Preparation of an ultrafine rebamipide ophthalmic suspension with high transparency. Biol. Pharm. Bull. 40:665–674, 2017.
39.
La GattaA., SchiraldiC., D'AgostinoA., PapaA., and De RosaM.Properties of newly-synthesized cationic semi-interpenetrating hydrogels containing either hyaluronan or chondroitin sulfate in a methacrylic matrix. J. Funct. Biomater. 3:225–238, 2012.
40.
AmbrosioL., BorzachielloA., NettiP.A., and NicolasL.Properties of new materials: rheological study on hyaluronic acid and its derivative solutions. J. Macromol. Sci. Pure. A36:991–1000, 1999.
41.
KrauseW.E., BellomoE.G., and ColbyR.H.Rheology of sodium hyaluronate under physiological conditions. Biomacromolecules. 2:65–69, 2001.
42.
Hill-BatorA., Misiuk-HojloM., MaryczK., and GrzesiakJ.Trehalose-based eye drops preserve viability and functionality of cultured human corneal epithelial cells during desiccation. Biomed. Res. Int. 2014:1–8, 2014.
43.
NakamuraM., HikidaM., NakanoT., et al.Characterization of water retentive properties of hyaluronan. Cornea. 12:433–436, 1993.
44.
LaurinoC., PalmieriB., and CoacciA.Efficacy, safety, and tolerance of a new injection technique for high- and low-molecular-weight. Hyaluronic acid hybrid complexes. Eplasty. 15:427–437, 2015.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
